Better Buy: Eli Lilly vs. Novo Nordisk

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) recently reported their second-quarter financial results. All eyes were on their respective GLP-1 businesses, as they are the leaders in this field and generate most of their revenue from these products. Eli Lilly's results impressed the market, sending the stock higher post-earnings. The opposite happened with Novo Nordisk, and the company extended the market losses it has experienced over the past two years. Will Eli Lilly and Novo Nordisk continue moving in opposite directions? Let's find out which of these stocks is the better buy right now. Image source: The Motley Fool.Eli Lilly's tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight management, is a direct competitor to Novo Nordisk's semaglutide, known under the brand names Ozempic and Wegovy. Tirzepatide has a different mechanism of action. It mimics the action of two gut hormones: GLP-1 and GIP, versus just one for semaglutide. This dual-pathway approach is one reason tirzepatide has proven more effective for chronic weight management. In a head-to-head study, it led to an average weight loss of 20.2% versus semaglutide's 13.7% after 72 weeks. Tirzepatide is posting much better sales as a result.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool